Madrigal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Madrigal Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. 

CEO
William J. Sibold
CEOWilliam J. Sibold
Employees
528
Employees528
Headquarters
West Conshohocken, Pennsylvania
HeadquartersWest Conshohocken, Pennsylvania
Founded
2000
Founded2000
Employees
528
Employees528

MDGL Key Statistics

Market cap
13.64B
Market cap13.64B
Price-Earnings ratio
-45.51
Price-Earnings ratio-45.51
Dividend yield
Dividend yield
Average volume
403.42K
Average volume403.42K
High today
$604.59
High today$604.59
Low today
$585.09
Low today$585.09
Open price
$591.63
Open price$591.63
Volume
246.98K
Volume246.98K
52 Week high
$604.59
52 Week high$604.59
52 Week low
$265.00
52 Week low$265.00

Stock Snapshot

The current Madrigal Pharmaceuticals(MDGL) stock price is $601.03, with a market capitalization of 13.64B. The stock trades at a price-to-earnings (P/E) ratio of -45.51.

During the trading session on 2025-11-26, Madrigal Pharmaceuticals(MDGL) shares reached a daily high of $604.59 and a low of $585.09. At a current price of $601.03, the stock is +2.7% higher than the low and still -0.6% under the high.

Trading volume for Madrigal Pharmaceuticals(MDGL) stock has reached 246.98K, versus its average volume of 403.42K.

The stock's 52-week range extends from a low of $265.00 to a high of $604.59.

The stock's 52-week range extends from a low of $265.00 to a high of $604.59.

MDGL News

Simply Wall St 3d
A Look at Madrigal Pharmaceuticals’s Valuation Following Positive Phase 3 Rezdiffra Results for MASH Cirrhosis

Madrigal Pharmaceuticals (MDGL) is drawing interest after sharing two-year results from its Phase 3 MAESTRO-NAFLD-1 trial at a major liver disease conference. T...

A Look at Madrigal Pharmaceuticals’s Valuation Following Positive Phase 3 Rezdiffra Results for MASH Cirrhosis
TipRanks 5d
Madrigal Pharmaceuticals CCO Makes a Significant Stock Sale!

New insider activity at Madrigal Pharmaceuticals ( (MDGL) ) has taken place on November 21, 2025. TipRanks Black Friday Sale Claim 60% off TipRanks Premium for...

TipRanks 5d
Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Madrigal Pharmaceuticals, with a price target of $620.00. TipRanks Black...

Analyst ratings

94%

of 17 ratings
Buy
94.1%
Hold
5.9%
Sell
0%

People also own

Based on the portfolios of people who own MDGL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.